NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma has introduced an ‘at-the-market’ equity program allowing the company to sell common shares through the TSX Venture Exchange to raise up to C$30 million. This program offers NervGen flexibility to secure additional financing for various corporate purposes, including research and development.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.